← Voltar ao feed

Science Corporation raises $400M Series D at $3.5B valuation for PRIMA retinal implant and bio-hybrid brain interface

1 fonte(s) · 1 atualização(ões) · publicado 17/11/2026 11:26 · coletado há 3 horas

Science Corporation, the medical technology start-up founded in 2021 by former Neuralink president Max Hodak, raised a $400 million Series D. A person familiar with the deal told TechCrunch the round values the company at $3.5 billion. Investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. The company's first product, PRIMA, is a retinal implant for age-related macular degeneration. It is approved in Europe and available in Germany, and a trial for Stargardt's disease has started. Science plans to seek US access through the FDA Humanitarian Device Exemption. This is business and funding news with no security incident, vulnerability or threat activity, so there is no direct threat to defenders.

Linha do tempo

  1. techcrunch.com ↗ · pub. 17/11/2026 11:26 · coletado 17/11 13:00 primeiro registro

    Science Corporation raises $400M Series D at $3.5B valuation for PRIMA retinal implant and bio-hybrid brain interface

    ler a análise desta fonte

    Science Corporation, the medical technology start-up founded in 2021 by former Neuralink president Max Hodak, raised a $400 million Series D. A person familiar with the deal told TechCrunch the round values the company at $3.5 billion. Investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. The company's first product, PRIMA, is a retinal implant for age-related macular degeneration. It is approved in Europe and available in Germany, and a trial for Stargardt's disease has started. Science plans to seek US access through the FDA Humanitarian Device Exemption. This is business and funding news with no security incident, vulnerability or threat activity, so there is no direct threat to defenders.